Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2004 3
2005 3
2006 5
2007 9
2008 11
2009 17
2010 26
2011 23
2012 22
2013 25
2014 32
2015 23
2016 32
2017 25
2018 28
2019 35
2020 43
2021 38
2022 38
2023 28
2024 26
2025 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

442 results

Results by year

Filters applied: . Clear all
Page 1
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.
Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, Führer D, Keam B, Bardet S, Sherman EJ, Tahara M, Hu MI, Singh R, Lin Y, Soldatenkova V, Wright J, Lin B, Maeda P, Capdevila J, Wirth LJ; LIBRETTO-531 Trial Investigators. Hadoux J, et al. N Engl J Med. 2023 Nov 16;389(20):1851-1861. doi: 10.1056/NEJMoa2309719. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870969 Clinical Trial.
Frameshifting dynamics.
Tinoco I Jr, Kim HK, Yan S. Tinoco I Jr, et al. Among authors: kim hk. Biopolymers. 2013 Dec;99(12):1147-66. doi: 10.1002/bip.22293. Biopolymers. 2013. PMID: 23722586 Free PMC article. Review.
Gadolinium as an MRI contrast agent.
Kim HK, Lee GH, Chang Y. Kim HK, et al. Future Med Chem. 2018 Mar 1;10(6):639-661. doi: 10.4155/fmc-2017-0215. Epub 2018 Feb 7. Future Med Chem. 2018. PMID: 29412006 Review.
Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate-Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factors (ENSEMBLE).
Kim NH, Lee J, Chon S, Yu JM, Jeong IK, Lim S, Kim WJ, Song K, Cho HC, Yu HM, Kim KA, Kim SS, Lee SH, Kim CH, Kwak SH, Lee YH, Chung CH, Lee S, Jin HY, Lee JH, Koh G, Kim SY, Kim J, Lee JH, Kim TN, Jeon HJ, Lee JH, Jeon JH, Yoo HJ, Kim HK, Park HK, Nam-Goong IS, Hong S, Ahn CW, Yu JH, Park JH, Park KG, Park CH, Joung KH, Ryu OH, Park KY, Hong EG, Cha BS, Won KC, Chung YS, Kim SG. Kim NH, et al. Among authors: kim hk. Endocrinol Metab (Seoul). 2024 Oct;39(5):722-731. doi: 10.3803/EnM.2024.1995. Epub 2024 Aug 22. Endocrinol Metab (Seoul). 2024. PMID: 39174014 Free PMC article.
442 results